US Court Provides Opportunity For Lupin And Zydus To Debut Generic Myrbetriq
Both Firms Launch 25mg Version ‘At-Risk’ With Litigation Ongoing As Injunction Denied
Lupin and Zydus are targeting a market worth at least $1bn a year – and more than $2.4bn all told – after both in quick succession announcing the launch of generic versions of Astellas Pharma’s Myrbetriq treatment for overactive bladder.
